296 related articles for article (PubMed ID: 16896664)
1. Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer.
Pfannenberg AC; Aschoff P; Brechtel K; Müller M; Bares R; Paulsen F; Scheiderbauer J; Friedel G; Claussen CD; Eschmann SM
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):36-44. PubMed ID: 16896664
[TBL] [Abstract][Full Text] [Related]
2. [Impact of PET/CT on precise radiotherapy planning for non-small cell lung cancer].
Gong HY; Yu JM; Fu Z; Li BS; Li JB; Liu TH
Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):54-7. PubMed ID: 16737623
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
[TBL] [Abstract][Full Text] [Related]
4. Impact of FDG PET/CT on delineation of the gross tumor volume for radiation planning in non-small-cell lung cancer.
Spratt DE; Diaz R; McElmurray J; Csiki I; Duggan D; Lu B; Delbeke D
Clin Nucl Med; 2010 Apr; 35(4):237-43. PubMed ID: 20305410
[TBL] [Abstract][Full Text] [Related]
5. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1432-41. PubMed ID: 16125870
[TBL] [Abstract][Full Text] [Related]
6. The impact of PET and PET/CT on treatment planning and prognosis of patients with NSCLC treated with radiation therapy.
Nawara C; Rendl G; Wurstbauer K; Lackner B; Rettenbacher L; Datz L; Studnicka M; Sedlmayer F; Pirich C
Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):191-201. PubMed ID: 22402822
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the utility of whole-body MRI with and without contrast-enhanced Quick 3D and double RF fat suppression techniques, conventional whole-body MRI, PET/CT and conventional examination for assessment of recurrence in NSCLC patients.
Ohno Y; Nishio M; Koyama H; Yoshikawa T; Matsumoto S; Takenaka D; Seki S; Tsubakimoto M; Sugimura K
Eur J Radiol; 2013 Nov; 82(11):2018-27. PubMed ID: 24012452
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced nonsmall cell lung cancer--initial results.
Plathow C; Aschoff P; Lichy MP; Eschmann S; Hehr T; Brink I; Claussen CD; Pfannenberg C; Schlemmer HP
Invest Radiol; 2008 May; 43(5):290-7. PubMed ID: 18424949
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy planning: PET/CT scanner performances in the definition of gross tumour volume and clinical target volume.
Brianzoni E; Rossi G; Ancidei S; Berbellini A; Capoccetti F; Cidda C; D'Avenia P; Fattori S; Montini GC; Valentini G; Proietti A; Algranati C
Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1392-9. PubMed ID: 16133395
[TBL] [Abstract][Full Text] [Related]
10. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
[TBL] [Abstract][Full Text] [Related]
11. Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging.
Pfannenberg AC; Aschoff P; Brechtel K; Müller M; Klein M; Bares R; Claussen CD; Eschmann SM
Br J Radiol; 2007 Jun; 80(954):437-45. PubMed ID: 17329683
[TBL] [Abstract][Full Text] [Related]
12. Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer.
Yang W; Fu Z; Yu J; Yuan S; Zhang B; Li D; Xing L; Zhao D; Mu D; Sun X; Fang Y; Huang Y; Li W
Lung Cancer; 2008 Jul; 61(1):35-43. PubMed ID: 18177978
[TBL] [Abstract][Full Text] [Related]
13. Comparison of whole-body PET/CT, dedicated high-resolution head and neck PET/CT, and contrast-enhanced CT in preoperative staging of clinically M0 squamous cell carcinoma of the head and neck.
Rodrigues RS; Bozza FA; Christian PE; Hoffman JM; Butterfield RI; Christensen CR; Heilbrun M; Wiggins RH; Hunt JP; Bentz BG; Hitchcock YJ; Morton KA
J Nucl Med; 2009 Aug; 50(8):1205-13. PubMed ID: 19617339
[TBL] [Abstract][Full Text] [Related]
14. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study.
van Der Wel A; Nijsten S; Hochstenbag M; Lamers R; Boersma L; Wanders R; Lutgens L; Zimny M; Bentzen SM; Wouters B; Lambin P; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):649-55. PubMed ID: 15708242
[TBL] [Abstract][Full Text] [Related]
15. [Impact of computed tomography (CT) and 18F-deoxyglucose-coincidence detection emission tomography (FDG-CDET) image fusion for optimisation of conformal radiotherapy in non-small-cell lung cancers].
Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
Cancer Radiother; 2005 Sep; 9(5):304-15. PubMed ID: 16087377
[TBL] [Abstract][Full Text] [Related]
16. Contrast-enhanced PET/MR imaging versus contrast-enhanced PET/CT in head and neck cancer: how much MR information is needed?
Kuhn FP; Hüllner M; Mader CE; Kastrinidis N; Huber GF; von Schulthess GK; Kollias S; Veit-Haibach P
J Nucl Med; 2014 Apr; 55(4):551-8. PubMed ID: 24491410
[TBL] [Abstract][Full Text] [Related]
17. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F
Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906
[TBL] [Abstract][Full Text] [Related]
18. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
Gillham C; Zips D; Pönisch F; Evers C; Enghardt W; Abolmaali N; Zöphel K; Appold S; Hölscher T; Steinbach J; Kotzerke J; Herrmann T; Baumann M
Radiother Oncol; 2008 Sep; 88(3):335-41. PubMed ID: 18514339
[TBL] [Abstract][Full Text] [Related]
19. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
20. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer.
Cerfolio RJ; Ojha B; Bryant AS; Raghuveer V; Mountz JM; Bartolucci AA
Ann Thorac Surg; 2004 Sep; 78(3):1017-23; discussion 1017-23. PubMed ID: 15337041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
